Dual and multi-drug delivery nanoparticles towards neuronal survival and synaptic repair
Among the macromolecular drug targets in neurodegenerative disorders, the neurotrophin brain-derived neurotrophic factor（BDNF） and its high-affinity tropomyosin-related kinase receptor（Trk B） present strong interest for nanomedicine development aiming at neuronal and synaptic repair. Currently, BDNF...
Saved in:
| Published in | Neural regeneration research Vol. 12; no. 6; pp. 886 - 889 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
India
Medknow Publications and Media Pvt. Ltd
01.06.2017
Medknow Publications & Media Pvt. Ltd Institut Galien Paris-Sud, CNRS UMR 8612, University of Paris-Sud, Université Paris-Saclay, LabEx LERMIT, Chatenay-Malabry cedex, France%Institute of Physics, ELI Beamlines, Academy of Sciences of the Czech Republic, Prague, Czech Republic Medknow Publications & Media Pvt Ltd Wolters Kluwer Medknow Publications |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1673-5374 1876-7958 |
| DOI | 10.4103/1673-5374.208546 |
Cover
Loading…
| Abstract | Among the macromolecular drug targets in neurodegenerative disorders, the neurotrophin brain-derived neurotrophic factor（BDNF） and its high-affinity tropomyosin-related kinase receptor（Trk B） present strong interest for nanomedicine development aiming at neuronal and synaptic repair. Currently, BDNF is regarded as the neurotrophic factor of highest therapeutic significance. However, BDNF has delivery problems as a protein drug. The enhanced activation of the transcription factor CREB（c AMP response element-binding protein） has been evidenced to increase the BDNF gene expression and hence the production of endogenous BDNF. We assume that BDNF delivery by nanocarriers and mitochondrial protection may provide high potential for therapeutic amelioration of the neuroregenerative strategies. Beneficial therapeutic outcomes may be expected for synergistic dual or multi-drug action aiming at（i） neurotrophic protein regulation in the central and peripheral nervous systems, and（ii） diminishment of the production of reactive oxygen species（ROS） and the oxidative damage in mitochondria. Our research strategy is based on a nanoarchitectonics approach for the design of nanomedicine assemblies by hierarchical self-assembly. We explore nanoarchitectonics concepts in soft-matter nanotechnology towards preparation of biodegradable self-assembled lipid nanostructures for safe neuro-therapeutic applications of multi-target nanomedicines. |
|---|---|
| AbstractList | Among the macromolecular drug targets in neurodegenerative disorders, the neurotrophin brain-derived neurotrophic factor (BDNF) and its high-affinity tropomyosin-related kinase receptor (TrkB) present strong interest for nanomedicine development aiming at neuronal and synaptic repair. Currently, BDNF is regarded as the neurotrophic factor of highest therapeutic significance. However, BDNF has delivery problems as a protein drug. The enhanced activation of the transcription factor CREB (cAMP response element-binding protein) has been evidenced to increase the BDNF gene expression and hence the production of endogenous BDNF. We assume that BDNF delivery by nanocarriers and mitochondrial protection may provide high potential for therapeutic amelioration of the neuroregenerative strategies. Beneficial therapeutic outcomes may be expected for synergistic dual or multi-drug action aiming at (i) neurotrophic protein regulation in the central and peripheral nervous systems, and (ii) diminishment of the production of reactive oxygen species (ROS) and the oxidative damage in mitochondria. Our research strategy is based on a nanoarchitectonics approach for the design of nanomedicine assemblies by hierarchical self-assembly. We explore nanoarchitectonics concepts in soft-matter nanotechnology towards preparation of biodegradable self-assembled lipid nanostructures for safe neuro-therapeutic applications of multi-target nanomedicines. Among the macromolecular drug targets in neurodegenerative disorders, the neurotrophin brain-derived neurotrophic factor (BDNF) and its high-affinity tropomyosin-related kinase receptor (TrkB) present strong interest for nanomedicine development aiming at neuronal and synaptic repair. Currently, BDNF is regarded as the neurotrophic factor of highest therapeutic significance. However, BDNF has delivery problems as a protein drug. The enhanced activation of the transcription factor CREB (cAMP response element-binding protein) has been evidenced to increase the BDNF gene expression and hence the production of endogenous BDNF. We assume that BDNF delivery by nanocarriers and mitochondrial protection may provide high potential for therapeutic amelioration of the neuroregenerative strategies. Beneficial therapeutic outcomes may be expected for synergistic dual or multi-drug action aiming at (i) neurotrophic protein regulation in the central and peripheral nervous systems, and (ii) diminishment of the production of reactive oxygen species (ROS) and the oxidative damage in mitochondria. Our research strategy is based on a nanoarchitectonics approach for the design of nanomedicine assemblies by hierarchical self-assembly. We explore nanoarchitectonics concepts in soft-matter nanotechnology towards preparation of biodegradable self-assembled lipid nanostructures for safe neuro-therapeutic applications of multi-target nanomedicines.Among the macromolecular drug targets in neurodegenerative disorders, the neurotrophin brain-derived neurotrophic factor (BDNF) and its high-affinity tropomyosin-related kinase receptor (TrkB) present strong interest for nanomedicine development aiming at neuronal and synaptic repair. Currently, BDNF is regarded as the neurotrophic factor of highest therapeutic significance. However, BDNF has delivery problems as a protein drug. The enhanced activation of the transcription factor CREB (cAMP response element-binding protein) has been evidenced to increase the BDNF gene expression and hence the production of endogenous BDNF. We assume that BDNF delivery by nanocarriers and mitochondrial protection may provide high potential for therapeutic amelioration of the neuroregenerative strategies. Beneficial therapeutic outcomes may be expected for synergistic dual or multi-drug action aiming at (i) neurotrophic protein regulation in the central and peripheral nervous systems, and (ii) diminishment of the production of reactive oxygen species (ROS) and the oxidative damage in mitochondria. Our research strategy is based on a nanoarchitectonics approach for the design of nanomedicine assemblies by hierarchical self-assembly. We explore nanoarchitectonics concepts in soft-matter nanotechnology towards preparation of biodegradable self-assembled lipid nanostructures for safe neuro-therapeutic applications of multi-target nanomedicines. Among the macromolecular drug targets in neurodegenerative disorders, the neurotrophin brain-derived neurotrophic factor (BDNF) and its high-affinity tropomyosin-related kinase receptor (TrkB) present strong interest for nanomedicine development aiming at neuronal and synaptic repair. Currently, BDNF is regarded as the neurotrophic factor of highest therapeutic significance. However, BDNF has delivery problems as a protein drug. The enhanced activation of the transcription factor CREB (cAMP response ele-ment-binding protein) has been evidenced to increase the BDNF gene expression and hence the production of endogenous BDNF. We assume that BDNF delivery by nanocarriers and mitochondrial protection may provide high potential for therapeutic amelioration of the neuroregenerative strategies. Beneficial therapeu-tic outcomes may be expected for synergistic dual or multi-drug action aiming at (i) neurotrophic protein regulation in the central and peripheral nervous systems, and (ii) diminishment of the production of reac-tive oxygen species (ROS) and the oxidative damage in mitochondria. Our research strategy is based on a nanoarchitectonics approach for the design of nanomedicine assemblies by hierarchical self-assembly. We explore nanoarchitectonics concepts in soft-matter nanotechnology towards preparation of biodegradable self-assembled lipid nanostructures for safe neuro-therapeutic applications of multi-target nanomedicines. Among the macromolecular drug targets in neurodegenerative disorders, the neurotrophin brain-derived neurotrophic factor（BDNF） and its high-affinity tropomyosin-related kinase receptor（Trk B） present strong interest for nanomedicine development aiming at neuronal and synaptic repair. Currently, BDNF is regarded as the neurotrophic factor of highest therapeutic significance. However, BDNF has delivery problems as a protein drug. The enhanced activation of the transcription factor CREB（c AMP response element-binding protein） has been evidenced to increase the BDNF gene expression and hence the production of endogenous BDNF. We assume that BDNF delivery by nanocarriers and mitochondrial protection may provide high potential for therapeutic amelioration of the neuroregenerative strategies. Beneficial therapeutic outcomes may be expected for synergistic dual or multi-drug action aiming at（i） neurotrophic protein regulation in the central and peripheral nervous systems, and（ii） diminishment of the production of reactive oxygen species（ROS） and the oxidative damage in mitochondria. Our research strategy is based on a nanoarchitectonics approach for the design of nanomedicine assemblies by hierarchical self-assembly. We explore nanoarchitectonics concepts in soft-matter nanotechnology towards preparation of biodegradable self-assembled lipid nanostructures for safe neuro-therapeutic applications of multi-target nanomedicines. |
| Audience | Academic |
| Author | Angelina Angelova Borislav Angelov |
| AuthorAffiliation | Institut Galien Paris-Sud, CNRS UMR 8612, University of Paris-Sud, Universite Paris-Saclay, LabEx LERMIT, Chatenay-Malabry cedex, France Institute of Physics, ELI Beamlines, Academy of Sciences of the Czech Republic, Prague, Czech Republic |
| AuthorAffiliation_xml | – name: Institut Galien Paris-Sud, CNRS UMR 8612, University of Paris-Sud, Université Paris-Saclay, LabEx LERMIT, Chatenay-Malabry cedex, France%Institute of Physics, ELI Beamlines, Academy of Sciences of the Czech Republic, Prague, Czech Republic – name: 2 Institute of Physics, ELI Beamlines, Academy of Sciences of the Czech Republic, Prague, Czech Republic – name: 1 Institut Galien Paris-Sud, CNRS UMR 8612, University of Paris-Sud, Université Paris-Saclay, LabEx LERMIT, Châtenay-Malabry cedex, France |
| Author_xml | – sequence: 1 givenname: Angelina surname: Angelova fullname: Angelova, Angelina – sequence: 2 givenname: Borislav surname: Angelov fullname: Angelov, Borislav |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28761415$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ktuL1DAUxousuBd990mKvgjSMffLi7Cst4UFXxR8C2madjN0ktmknWX2rze1M6OziJTScPL7vtNz-M6LEx-8LYqXECwIBPg9ZBxXFHOyQEBQwp4UZ1BwVnFJxUk-769Pi_OUlgBQIRF-VpyiDEEC6Vnx8-Oo-1L7plyN_eCqJo5d2djebWzcll77sNZxcKa3qRzCvY5NKr0dY_BZlsa4cZudPm29XmeyjHatXXxePG11n-yL3fei-PH50_err9XNty_XV5c3lWEIDJVtJGwxh4hyWxsJRcMYAAiDluOWMmsQqjVnXDa4ronR-YUSTlXaAMoIviiuZ98m6KVaR7fScauCdup3IcRO7QZQvJYISkkIEC2hnEhiczvNIcYtI6DNXh9mr_VYr2xjrB-i7o9Mj2-8u1Vd2ChKIRGUZ4N3s8G99q32nVqGMeZNJfXQpeVD2i6VRQBykGekmX67axfD3WjToFYuGdv32tswJgUlokgIQGRG3zxCD84IC8Sk4JT-oTqdx3W-DfkvzWSqLonkAjMhcaYW_6Dy09iVMzlgrcv1I8Grv9dy2Mc-RRkAM2BiSCna9oBAoKagqimJakqimoOaJeyRxLhBDy5Mi3X9_4Svd8Lb4Ls7l5e8b8Y4opJIyfEvY0301w |
| CitedBy_id | crossref_primary_10_1016_j_biopha_2020_109906 crossref_primary_10_3233_ADR_180091 crossref_primary_10_1016_j_arabjc_2021_103426 crossref_primary_10_4103_1673_5374_230275 crossref_primary_10_1021_acs_langmuir_7b02486 crossref_primary_10_1080_1061186X_2017_1367006 crossref_primary_10_1002_adhm_201801000 crossref_primary_10_1016_j_mencom_2021_04_043 crossref_primary_10_1021_acs_jpcb_0c01618 crossref_primary_10_1038_s42004_023_01043_9 crossref_primary_10_4103_1673_5374_336132 crossref_primary_10_3390_pharmaceutics13020226 crossref_primary_10_4155_tde_2020_0082 crossref_primary_10_1021_acsabm_0c00269 crossref_primary_10_3390_nano10030510 crossref_primary_10_3390_pharmaceutics15020565 crossref_primary_10_1016_j_phrs_2021_105469 crossref_primary_10_3390_molecules24173058 crossref_primary_10_1016_j_jchemneu_2020_101795 crossref_primary_10_4103_jpbs_jpbs_1184_23 crossref_primary_10_3390_ijms19082295 crossref_primary_10_1016_j_mcn_2018_03_010 crossref_primary_10_4103_1673_5374_354517 crossref_primary_10_1016_j_smaim_2022_03_001 crossref_primary_10_1021_acsomega_7b01935 crossref_primary_10_1002_adtp_202400093 crossref_primary_10_2217_nnm_2018_0192 crossref_primary_10_3390_nano13233004 crossref_primary_10_1080_02652048_2017_1370029 crossref_primary_10_4103_1673_5374_239439 crossref_primary_10_3390_medicines5040126 crossref_primary_10_1080_10408398_2022_2155106 crossref_primary_10_3390_polym13111747 crossref_primary_10_3390_ijms23031047 crossref_primary_10_3390_nano10050898 crossref_primary_10_1007_s12640_021_00468_1 crossref_primary_10_1007_s13346_022_01174_x crossref_primary_10_1021_acsomega_8b03101 crossref_primary_10_3389_fcell_2021_617984 crossref_primary_10_1142_S1793984423500162 crossref_primary_10_1007_s10904_020_01506_9 crossref_primary_10_1016_j_jcis_2020_04_015 crossref_primary_10_1016_j_phrs_2022_106099 crossref_primary_10_1021_acsami_9b21783 crossref_primary_10_1021_acssuschemeng_1c04706 crossref_primary_10_1080_17425247_2023_2286369 crossref_primary_10_1016_j_molliq_2019_01_124 crossref_primary_10_1080_01932691_2018_1484295 crossref_primary_10_1007_s10904_018_1023_4 crossref_primary_10_1002_cnma_201900468 crossref_primary_10_3390_pharmaceutics16010033 crossref_primary_10_3390_nano12132267 crossref_primary_10_3390_ph16030474 crossref_primary_10_1016_j_mencom_2021_07_023 crossref_primary_10_1016_j_colsurfa_2019_124154 crossref_primary_10_1021_acschemneuro_1c00181 crossref_primary_10_1016_j_ejps_2018_08_020 crossref_primary_10_1016_j_jpcs_2018_05_029 crossref_primary_10_1016_j_mcn_2018_01_003 crossref_primary_10_3390_pharmaceutics15030732 crossref_primary_10_1016_j_ejbt_2022_03_001 crossref_primary_10_1038_s41390_023_02513_5 crossref_primary_10_1089_adt_2022_025 crossref_primary_10_1515_ntrev_2022_0143 crossref_primary_10_3390_ijms22063161 crossref_primary_10_1007_s13346_022_01256_w crossref_primary_10_1002_jbm_a_37135 crossref_primary_10_1021_acs_molpharmaceut_0c00755 crossref_primary_10_3390_ijms22126347 crossref_primary_10_3390_jnt2010001 |
| Cites_doi | 10.1021/pr5006982 10.1021/nn5012946 10.1038/ncomms2238 10.1038/nrn3505 10.1016/j.jalz.2016.08.001 10.2174/1570159X14666160414111821 10.1007/s11095-016-2080-4 10.1016/j.ijpharm.2016.08.002 10.1039/C5SM00169B 10.1038/nrn1078 10.3390/pharmaceutics5010127 10.1074/jbc.M113.526129 10.1111/j.1460-9568.2004.03578.x 10.1016/j.biomaterials.2015.11.060 10.1016/j.drudis.2013.07.010 10.1016/j.molliq.2016.11.064 10.1007/s10904-014-0143-8 10.1016/j.nano.2012.05.007 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2017 Medknow Publications and Media Pvt. Ltd. 2017. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Copyright © Wanfang Data Co. Ltd. All Rights Reserved. Copyright: © Neural Regeneration Research 2017 |
| Copyright_xml | – notice: COPYRIGHT 2017 Medknow Publications and Media Pvt. Ltd. – notice: 2017. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved. – notice: Copyright: © Neural Regeneration Research 2017 |
| DBID | 2RA 92L CQIGP W91 ~WA AAYXX CITATION NPM 3V. 7X7 7XB 88G 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ K9. M0S M2M PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 2B. 4A8 92I 93N PSX TCJ 5PM DOA |
| DOI | 10.4103/1673-5374.208546 |
| DatabaseName | 维普期刊资源整合服务平台 中文科技期刊数据库-CALIS站点 维普中文期刊数据库 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Psychology Database (Alumni) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Psychology Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic Wanfang Data Journals - Hong Kong WANFANG Data Centre Wanfang Data Journals 万方数据期刊 - 香港版 China Online Journals (COJ) China Online Journals (COJ) PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Psychology ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology |
| DocumentTitleAlternate | Dual and multi-drug delivery nanoparticles towards neuronal survival and synaptic repair |
| EISSN | 1876-7958 |
| EndPage | 889 |
| ExternalDocumentID | oai_doaj_org_article_7b921994408f457494e8d6a7133f640f PMC5514857 zgsjzsyj_e201706005 A497836893 28761415 10_4103_1673_5374_208546 672594997 |
| Genre | Journal Article Review |
| GrantInformation_xml | – fundername: AA is supported by CNRS. BA is supported by the Czech Science Foundation Grant GACR 17-00973S and the projects ELI - Extreme Light Infrastructure – phase 2(CZ.02.1.01/0.0/0.0/15_008/0000162); ELIBIO (CZ.02.1.01/0.0/0.0/15_003/0000447) from the European Regional Development Fund |
| GroupedDBID | --- --K 0R~ 123 1B1 2B. 2C~ 2RA 4.4 53G 5RS 5VR 5VS 7X7 8FI 8FJ 92F 92I 92L 93N 93R AAEDT AAKAS AALRI AAXUO ABUWG ABXLX ACGFS ADBBV ADMUD ADRAZ ADZCM AENEX AFKRA AFUIB ALMA_UNASSIGNED_HOLDINGS AZQEC BAWUL BENPR CCEZO CCPQU CHBEP CIEJG CQIGP CS3 CW9 DIK DU5 DWQXO EBS EJD EMOBN EO8 FA0 FDB FYUFA GNUQQ GROUPED_DOAJ GX1 HMCUK HYE HZ~ IAO IEA IHE IHR IPNFZ ITC KQ8 M2M M41 M48 M5~ NQ- O9- OK1 OVD PIMPY PSYQQ RIG RMW ROL RPM RPZ TCJ TEORI TGQ UKHRP W3E W91 WFFXF ~WA -SE -S~ AAYXX ABWVN ACRPL ADJBI ADNMO ALIPV CAJEE CITATION H13 PGMZT PHGZM PHGZT Q-- U1G U5O AAXDM NPM PMFND 3V. 7XB 8FK K9. PKEHL PQEST PQQKQ PQUKI PRINS Q9U 7X8 4A8 PSX 5PM PUEGO |
| ID | FETCH-LOGICAL-c620t-ed91f371257ebc918d6600230f73f56ec22ba7679d3bb4cab4c191c22b5d05643 |
| IEDL.DBID | M48 |
| ISSN | 1673-5374 |
| IngestDate | Wed Aug 27 01:31:54 EDT 2025 Thu Aug 21 14:35:25 EDT 2025 Thu May 29 04:06:13 EDT 2025 Thu Jul 10 17:03:10 EDT 2025 Fri Jul 25 19:42:42 EDT 2025 Tue Jun 17 21:09:55 EDT 2025 Tue Jun 10 20:20:14 EDT 2025 Thu Jan 02 22:42:21 EST 2025 Tue Jul 01 03:20:14 EDT 2025 Thu Apr 24 23:08:13 EDT 2025 Wed Feb 14 10:00:44 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | CREB macromolecular drugs neurotrophic factor BDNF delivery combination therapy nanomedicine neuroprotective lipid nanocarriers |
| Language | English |
| License | This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c620t-ed91f371257ebc918d6600230f73f56ec22ba7679d3bb4cab4c191c22b5d05643 |
| Notes | neuronal synaptic repair neurotrophic neurotrophin mitochondria CREB biodegradable endogenous aiming Among the macromolecular drug targets in neurodegenerative disorders, the neurotrophin brain-derived neurotrophic factor（BDNF） and its high-affinity tropomyosin-related kinase receptor（Trk B） present strong interest for nanomedicine development aiming at neuronal and synaptic repair. Currently, BDNF is regarded as the neurotrophic factor of highest therapeutic significance. However, BDNF has delivery problems as a protein drug. The enhanced activation of the transcription factor CREB（c AMP response element-binding protein） has been evidenced to increase the BDNF gene expression and hence the production of endogenous BDNF. We assume that BDNF delivery by nanocarriers and mitochondrial protection may provide high potential for therapeutic amelioration of the neuroregenerative strategies. Beneficial therapeutic outcomes may be expected for synergistic dual or multi-drug action aiming at（i） neurotrophic protein regulation in the central and peripheral nervous systems, and（ii） diminishment of the production of reactive oxygen species（ROS） and the oxidative damage in mitochondria. Our research strategy is based on a nanoarchitectonics approach for the design of nanomedicine assemblies by hierarchical self-assembly. We explore nanoarchitectonics concepts in soft-matter nanotechnology towards preparation of biodegradable self-assembled lipid nanostructures for safe neuro-therapeutic applications of multi-target nanomedicines. 11-5422/R ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 Author contributions: AA and BA framed the concept of the review, wrote the paper, and approved the final manuscript. |
| ORCID | 0000-0002-0285-0637 |
| OpenAccessLink | https://doaj.org/article/7b921994408f457494e8d6a7133f640f |
| PMID | 28761415 |
| PQID | 2382698755 |
| PQPubID | 4671210 |
| PageCount | 4 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_7b921994408f457494e8d6a7133f640f pubmedcentral_primary_oai_pubmedcentral_nih_gov_5514857 wanfang_journals_zgsjzsyj_e201706005 proquest_miscellaneous_1925288049 proquest_journals_2382698755 gale_infotracmisc_A497836893 gale_infotracacademiconefile_A497836893 pubmed_primary_28761415 crossref_primary_10_4103_1673_5374_208546 crossref_citationtrail_10_4103_1673_5374_208546 chongqing_primary_672594997 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2017-06-01 |
| PublicationDateYYYYMMDD | 2017-06-01 |
| PublicationDate_xml | – month: 06 year: 2017 text: 2017-06-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | India |
| PublicationPlace_xml | – name: India – name: Mumbai |
| PublicationTitle | Neural regeneration research |
| PublicationTitleAlternate | Neural Regeneration Research |
| PublicationTitle_FL | Neural Regeneration Research |
| PublicationYear | 2017 |
| Publisher | Medknow Publications and Media Pvt. Ltd Medknow Publications & Media Pvt. Ltd Institut Galien Paris-Sud, CNRS UMR 8612, University of Paris-Sud, Université Paris-Saclay, LabEx LERMIT, Chatenay-Malabry cedex, France%Institute of Physics, ELI Beamlines, Academy of Sciences of the Czech Republic, Prague, Czech Republic Medknow Publications & Media Pvt Ltd Wolters Kluwer Medknow Publications |
| Publisher_xml | – name: Medknow Publications and Media Pvt. Ltd – name: Medknow Publications & Media Pvt. Ltd – name: Institut Galien Paris-Sud, CNRS UMR 8612, University of Paris-Sud, Université Paris-Saclay, LabEx LERMIT, Chatenay-Malabry cedex, France%Institute of Physics, ELI Beamlines, Academy of Sciences of the Czech Republic, Prague, Czech Republic – name: Medknow Publications & Media Pvt Ltd – name: Wolters Kluwer Medknow Publications |
| References | key-10.4103/1673-5374.208546-18 key-10.4103/1673-5374.208546-19 key-10.4103/1673-5374.208546-16 key-10.4103/1673-5374.208546-17 key-10.4103/1673-5374.208546-7 key-10.4103/1673-5374.208546-8 key-10.4103/1673-5374.208546-9 key-10.4103/1673-5374.208546-3 key-10.4103/1673-5374.208546-4 key-10.4103/1673-5374.208546-5 key-10.4103/1673-5374.208546-6 key-10.4103/1673-5374.208546-10 key-10.4103/1673-5374.208546-11 key-10.4103/1673-5374.208546-1 key-10.4103/1673-5374.208546-2 key-10.4103/1673-5374.208546-14 key-10.4103/1673-5374.208546-15 key-10.4103/1673-5374.208546-12 key-10.4103/1673-5374.208546-13 27075203 - Curr Neuropharmacol. 2017;15(1):166-173 23674053 - Nat Rev Neurosci. 2013 Jun;14(6):401-16 27599210 - Alzheimers Dement. 2017 May;13(5):582-591 26903794 - Front Neurosci. 2016 Feb 09;10:26 12671646 - Nat Rev Neurosci. 2003 Apr;4(4):299-309 27995523 - Pharm Res. 2017 Feb;34(2):492-505 15341590 - Eur J Neurosci. 2004 Sep;20(5):1189-96 25820228 - Soft Matter. 2015 May 14;11(18):3686-92 24302729 - J Biol Chem. 2014 Jan 17;289(3):1213-26 24742149 - ACS Nano. 2014 May 27;8(5):5216-26 24300402 - Pharmaceutics. 2013 Feb 08;5(1):127-67 23891881 - Drug Discov Today. 2013 Dec;18(23-24):1263-71 22640910 - Nanomedicine. 2012 Sep;8 Suppl 1:S51-8 27498282 - Int J Pharm. 2016 Sep 25;511(2):969-82 23212379 - Nat Commun. 2012;3:1250 26706474 - Biomaterials. 2016 Feb;80:33-45 25271054 - J Proteome Res. 2014 Dec 5;13(12):5707-14 |
| References_xml | – ident: key-10.4103/1673-5374.208546-19 doi: 10.1021/pr5006982 – ident: key-10.4103/1673-5374.208546-2 doi: 10.1021/nn5012946 – ident: key-10.4103/1673-5374.208546-7 doi: 10.1038/ncomms2238 – ident: key-10.4103/1673-5374.208546-13 doi: 10.1038/nrn3505 – ident: key-10.4103/1673-5374.208546-8 doi: 10.1016/j.jalz.2016.08.001 – ident: key-10.4103/1673-5374.208546-17 doi: 10.2174/1570159X14666160414111821 – ident: key-10.4103/1673-5374.208546-10 doi: 10.1007/s11095-016-2080-4 – ident: key-10.4103/1673-5374.208546-11 doi: 10.1016/j.ijpharm.2016.08.002 – ident: key-10.4103/1673-5374.208546-1 doi: 10.1039/C5SM00169B – ident: key-10.4103/1673-5374.208546-6 doi: 10.1038/nrn1078 – ident: key-10.4103/1673-5374.208546-18 – ident: key-10.4103/1673-5374.208546-9 doi: 10.3390/pharmaceutics5010127 – ident: key-10.4103/1673-5374.208546-16 doi: 10.1074/jbc.M113.526129 – ident: key-10.4103/1673-5374.208546-14 doi: 10.1111/j.1460-9568.2004.03578.x – ident: key-10.4103/1673-5374.208546-12 doi: 10.1016/j.biomaterials.2015.11.060 – ident: key-10.4103/1673-5374.208546-4 doi: 10.1016/j.drudis.2013.07.010 – ident: key-10.4103/1673-5374.208546-3 doi: 10.1016/j.molliq.2016.11.064 – ident: key-10.4103/1673-5374.208546-5 doi: 10.1007/s10904-014-0143-8 – ident: key-10.4103/1673-5374.208546-15 doi: 10.1016/j.nano.2012.05.007 – reference: 24302729 - J Biol Chem. 2014 Jan 17;289(3):1213-26 – reference: 25271054 - J Proteome Res. 2014 Dec 5;13(12):5707-14 – reference: 23674053 - Nat Rev Neurosci. 2013 Jun;14(6):401-16 – reference: 26903794 - Front Neurosci. 2016 Feb 09;10:26 – reference: 27075203 - Curr Neuropharmacol. 2017;15(1):166-173 – reference: 23212379 - Nat Commun. 2012;3:1250 – reference: 25820228 - Soft Matter. 2015 May 14;11(18):3686-92 – reference: 15341590 - Eur J Neurosci. 2004 Sep;20(5):1189-96 – reference: 24742149 - ACS Nano. 2014 May 27;8(5):5216-26 – reference: 23891881 - Drug Discov Today. 2013 Dec;18(23-24):1263-71 – reference: 27498282 - Int J Pharm. 2016 Sep 25;511(2):969-82 – reference: 27995523 - Pharm Res. 2017 Feb;34(2):492-505 – reference: 26706474 - Biomaterials. 2016 Feb;80:33-45 – reference: 24300402 - Pharmaceutics. 2013 Feb 08;5(1):127-67 – reference: 27599210 - Alzheimers Dement. 2017 May;13(5):582-591 – reference: 22640910 - Nanomedicine. 2012 Sep;8 Suppl 1:S51-8 – reference: 12671646 - Nat Rev Neurosci. 2003 Apr;4(4):299-309 |
| SSID | ssj0058923 |
| Score | 2.341815 |
| SecondaryResourceType | review_article |
| Snippet | Among the macromolecular drug targets in neurodegenerative disorders, the neurotrophin brain-derived neurotrophic factor（BDNF） and its high-affinity... Among the macromolecular drug targets in neurodegenerative disorders, the neurotrophin brain-derived neurotrophic factor (BDNF) and its high-affinity... |
| SourceID | doaj pubmedcentral wanfang proquest gale pubmed crossref chongqing |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 886 |
| SubjectTerms | Amyotrophic lateral sclerosis BDNF delivery; neuroprotective lipid nanocarriers; neurotrophic factor; CREB; nanomedicine; macromolecular drugs; combination therapy BDNF基因 Brain-derived neurotrophic factor Drugs Gene expression Invited Review Kinases Lipids Mitochondria Mutation Nanoparticles Nanotechnology Neurodegeneration Neurogenesis Neurological disorders Neurons Oxidative stress Peptides Physiological aspects Proteins Reactive oxygen species Synaptic transmission 修复 神经退行性疾病 突触 纳米颗粒 细胞存活 脑源性神经营养因子 蛋白药物 |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELbQSkhcELA8wi4oSCsQh9DEcez4WB6rFQdOrNSb5fjR3dXiQtOAur-eGScNDQhx4dCLY6fxzHhmvnbyDSEn0oNXbKzNtC5kxrx0WeOlyXhDLQQoCKA-Vvl-4mfn7OOiWuy1-sKasJ4euBfcTDSSIn8ty2vPKsEkc7XlGrGV5yz36H0h5u3AVO-Dq1rGxm4FF2VWlYL1f1CyIi9n49gbbE_JIqnCxSosv0GomASnyOH_p6feC1W_l1He_qGD12G5F6FO75G7Q2qZzvst3Se3XHhADucBYPWXbfoyjcWe8Vf0Q7J438FUHWwaKwozu-6WqXXXWKWxTYMOgKWHkrl0Eytr2zRSX-I3tB34l-_D-nYbNLgdk64hsF2uH5Lz0w-f351lQ5OFzHCabzJnZeFLAXmOcI2RBQiXR2DiRekr7gyljRZcSFs2DTMaPgDxcLSykDyx8hE5CKvgnpC0xjbhvjAm94zZkoLSNS2Z16WT2niekKNR0uprT6ahuAAABrBLJGS2k70yAz85tsm4VoBTUHMKNadQc6rXXEJejyt2t_v73LeoznEesmrHAbA1NQhU_cvWEvIKjUHh2YdHM3p4hQG2jyxaas7iSzGQAibkeDITzqyZXt6Zkxp8RqsgeaJcAn6sEvJivIwrsQ4uuFXXKsjHKwoul8mEPO6tb9wSYF_ItQpYLSZ2Odnz9Eq4vIiM4pg21xWo4GSw4F9PdbNsr27a7ZVytKdayqun_0OWR-QO3rCvujsmB5t1555Bfrdpnsej_BPDUUfd priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCIkLAsojtKAgVSAOYfNw7PUJLY-q4sCJSnuzHD-2rVqn3eyCtr-eGcebNiA47MWxs7ZnMjOfM_mGkAPhwCo2xmRKFSKjTtiscUJnrCkNOChwoC5k-X5nR8f027yexwO3LqZVbm1iMNSm1XhGPgHXUjIAyHX98fIqw6pR-HY1ltC4S-4hdRmCLz4fAFc9FaG8W8F4ldUVp_1rSlrk1WRo-4BFKmmgVjhp_eIKHMbIRQUm_7_t9S2H9Wcy5f1fyjvlF7f81OEj8jAGmOms14jH5I71T8juzAO4vtikb9OQ8hnO0nfJ_Msauipv0pBXmJnlepEae465GpvUKw-IOibOpauQX9ulgQAT_6Fbg5X5Gcd3G6_A-Oh0Ce7tdPmUHB9-_fH5KIulFjLNynyVWSMKV3GIdrhttCimhrEATxyvXM2sLstGccaFqZqGagU_AHrYWhsIoWj1jOz41tsXJJ1isXBXaJ07Sk1VguhVWVGnKiuUdiwhe8NOy8ueUkMyDjAMwBdPyGS791JHlnIslnEuAa2g5CRKTqLkZC-5hLwfRmxv9---n1CcQz_k1g4N7XIh44ZK3ogSGZNpPnW05lRQC9uhEM07RnOXkHeoDBItAExNq_ghAywfubTkjIZPYyAQTMj-qCc8uXp8eatOMlqOTt7oeULeDJdxJGbDeduuOwlReV2C4aUiIc977RuWBAgYIq4CRvORXo7WPL7iT08CrzgGz9MaRHAQNfhmVteL7uy625xJW_aES3n98v-z3yMPsGufVbdPdlbLtX0F8duqeR0e0t9A_UER priority: 102 providerName: ProQuest |
| Title | Dual and multi-drug delivery nanoparticles towards neuronal survival and synaptic repair |
| URI | http://lib.cqvip.com/qk/88507X/201706/672594997.html https://www.ncbi.nlm.nih.gov/pubmed/28761415 https://www.proquest.com/docview/2382698755 https://www.proquest.com/docview/1925288049 https://d.wanfangdata.com.cn/periodical/zgsjzsyj-e201706005 https://pubmed.ncbi.nlm.nih.gov/PMC5514857 https://doaj.org/article/7b921994408f457494e8d6a7133f640f |
| Volume | 12 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELfYJiReEDA-wkYVpAnEQ7Z8OHb9hDroNCExIcRE3yzHsbtNxWVJC3R_PXdOmi0wJB7ah_icxHdn3_2c8x0he8LCqliUZaRUIiJqhYkKK3TEirQEAwUG1Poo3xN2fEo_TPLJ9fHoloH1rdAO60mdVrP9X5ertzDhwX_dp0mcHSSMZ1GecdwiGeaUbZAtsEscCzl8pN03hXwofLG3jrr5aHnrHTDRwtncTS_BfPQMls_r__fqfcN8_Rlaefencla56Q2rdfSA3G_dzXDU6MdDcse4R2R75ABqf1uFr0IfAOp31rfJ5P0SSJUrQx9lGJXVchqWZoaRG6vQKQf4ug2jCxc-2rYOfTpMfEK9hDXnR9u_XjkFS5EOKzB259Vjcno0_vLuOGoLL0SapfEiMqVIbMbB9-Gm0CIZlox5sGJ5ZnNmdJoWijMuyqwoqFbwA9iHV_MSHCqaPSGbbu7MMxIOsXS4TbSOLaVlloIiqDSjVmVGKG1ZQHY6TsvvTYINyTiAMoBiPCAHa95L3eYsx9IZMwnYBSUnUXISJScbyQXkTddjfbt_0x6iODs6zLTtL8yrqWwZKnkhUsyfTOOhpTmnghpgh0JsbxmNbUBeozJI1FB4Na3aYw0wfMysJUfUH5QBtzAguz1KmMe637xWJ7meBhIcqpQJwJR5QF52zdgTY-OcmS9rCT56nsIyTEVAnjba1w0J8DD4Xwn05j297I253-LOz3yWcXSlhzmIYK_V4Ou3uprWF1f16kKatEm_FOfP_5sNO-Qe9mrC7XbJ5qJamhfg2C2KAdngEz4gW4fjk0-fB357ZODnMPx_zca_AbU-TB0 |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKEYILAsojtECQCohD2MRx4s0BoYVStbT01Ep7cx0_tq2Kt93sUm1_FL-RGefRLghuPezF9mRtz2S-GWc8Q8h6YUErllpHUiZFxGxhotIWKspLqgGgAECtj_Ldy7cO2LdhNlwiv9q7MBhW2epEr6j1WOEZeQ-ghebgIGfZp7PzCKtG4dfVtoRGLRY7Zn4BLlv1cXsD-PuG0s2v-1-2oqaqQKRyGk8jo4vEphyAnZtSFUlf57m3xC1PbZYbRWkpec4LnZYlUxJ-4NNga6bBWmApPPcWuQ3AG2MIIR92Dl7WL3w5uSTnaZSlnNWfRVkSp72u7QMWxWQ-lcPR2I3OAaAWINFXDvgbH64B5J_Bm3cupLPSja7h4uYDcr8xaMNBLYEPyZJxj8jKwIEz_2Mevg19iKk_u18hw40ZDJVOhz6OMdKT2SjU5hRjQ-ahkw48-CZQL5z6eN4q9Ak38R-qGWi1nw19NXcSlJ0KJwCnx5PH5OBGmPCELLuxM89I2Mfi5DZRKraM6ZSCqEmaMitTU0hl84CsdjstzuoUHiLn4PaBs8cD0mv3XqgmKzoW5zgV4B0h5wRyTiDnRM25gLzvKNrH_XvsZ2RnNw5zefuG8WQkmg0VvCwoZmhmcd-yjLOCGdgOiacHNmexDcg7FAaBGgempmRzcQKWj7m7xID5qzhgeAZkbWEkaAq12N2Kk2g0VSWu3quAvO66kRKj75wZzyoBXkBGQdGzIiBPa-nrlgQeN1h4CVDzBblcWPNijzs-8nnM0VjvZ8CC9UaCr2Z1OapOLqv5iTC0TvAUZ8__P_tX5O7W_vddsbu9t7NK7iFZHdG3Rpank5l5AbbjtHzpX9iQHN60hvgNgWx9Lg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKEYgLAsojtECQCohD2MRx7PUBoYWlaimqOFBpb67jx7ZV8babXartT-PXMXYe7YLg1kMufiS2ZzzfjDOeQWiTW5CKpdaJlBlPiOUmKS1XCS2xBoACALXBy3ePbu-TL6NitIJ-tXdhvFtlKxODoNYT5c_IewAtmIKBXBQ927hFfBtufTg9S3wGKf-ntU2nUbPIrlmcg_lWvd8ZAq1fYbz1-fun7aTJMJAoitNZYjTPbM4A5JkpFc_6mtKglVuW24IahXEpGWVc52VJlIQH7BtfWmjQHEgO772BbrIcYBP2Eht1xl7R5yG1XEZZnhQ5I_UvUpKlea8re-cTZJIQ1uFw4sZnAFZL8BiyCPyNFVfA8k9Hzlvn0lnpxlcwcuseutsot_Gg5sb7aMW4B2ht4MCw_7GIX8fB3TSc46-h0XAOTaXTcfBpTPR0Po61OfF-IovYSQfWfOO0F8-Cb28Vh-Cb_gvVHCTcz6Z_tXASBJ-KpwCtR9OHaP9aiPAIrbqJM09Q3PeJym2mVGoJ0TkGtpM4J1bmhktlaYTWu5UWp3U4D0EZmIBg-LEI9dq1F6qJkO4TdZwIsJQ85YSnnPCUEzXlIvS269G-7t9tP3pydu18XO9QMJmORbOggpUc-2jNJO1bUjDCiYHlkP4kwVKS2gi98cwgvPSBoSnZXKKA6fs4XmJAwrUcUEIjtLHUEqSGWq5u2Uk0UqsSl3ssQi-7at_Te-I5M5lXAiyCAoPQJzxCj2vu66YE1jdoexn0Zkt8uTTn5Rp3dBhimnvFvV8ACTYbDr4c1cW4Or6oFsfC4DrYU1o8_f_oX6DbIBvE15293XV0x_eqnfs20OpsOjfPQI2clc_Dfo3RwXULiN-crYFk |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dual+and+multi-drug+delivery+nanoparticles+towards+neuronal+survival+and+synaptic+repair&rft.jtitle=Neural+regeneration+research&rft.au=Angelova%2C+Angelina&rft.au=Angelov%2C+Borislav&rft.date=2017-06-01&rft.pub=Medknow+Publications+and+Media+Pvt.+Ltd&rft.issn=1673-5374&rft.volume=12&rft.issue=6&rft.spage=886&rft_id=info:doi/10.4103%2F1673-5374.208546&rft.externalDocID=A497836893 |
| thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F88507X%2F88507X.jpg http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzgsjzsyj-e%2Fzgsjzsyj-e.jpg |